Cefepime Versus Carbapenem Therapy for the Treatment of Invasive Infections With Inducible Chromosomal AmpC-Producing Enterobacterales: A Systematic Review and Meta-analysis.

No statistically significant difference in all-cause mortality was observed between cefepime and carbapenem treatment (log OR, 0.15 [95% CI, −.33 to .64]; P = .54), although a nonsignificant trend favored cefepime, particularly in the subgroup of larger observational studies (n ≥ 50 patients) and more recent studies (published after 2019).

also in 5,406 other papers

Notably, the larger and more recent observational studies in our analysis suggested a trend favoring cefepime over carbapenems, though this did not reach statistical significance.

also in 111,027 other papers